428 Oakmead Parkway
About Apostle Inc.
Apostle is a biotechnology company developing a novel bioinformatics-enabled nanotechnology aimed for early cancer detection. This new approach will enable the early assessment of the cancerous signals in human peripheral blood plasma, which is believed to have a significant impact on the global healthcare landscape in both developed countries and emerging markets.
March 28, 2017
Founder and CEO: Dr. David Dongliang Ge
VP, Chemistry: Bo Zhang, PhD.
VP, Bioinformatics: Xin Guo, PhD.
Chief Medical Advisor: Wenqi Zeng, MD. PhD. FACMG
7 articles with Apostle Inc.
Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...
10/5/2018Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
1/29/2018Apostle, headquartered in Sunnyvale, Calif., hopes to file an IPO or establish other strong business collaborative routes in five years.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.